Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on developing therapeutics for rare diseases affecting bone health and blood vessel function, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's CEO and Chairman, Doug Treco, Ph.D., will engage in a fireside chat scheduled for Monday, April 7, 2025, from 2:15-2:55pm ET. Investors and interested parties can access the live webcast through the Investor Relations section of Inozyme's website under events. A replay will be available for a time following the presentation.
Inozyme Pharma (Nasdaq: INZY), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di terapie per malattie rare che influenzano la salute delle ossa e la funzione dei vasi sanguigni, ha annunciato la sua partecipazione alla 24a Conferenza Virtuale Annuale di Needham sulla Salute.
Il CEO e Presidente dell'azienda, Doug Treco, Ph.D., parteciperà a una chiacchierata informale programmata per lunedì 7 aprile 2025, dalle 14:15 alle 14:55 ET. Gli investitori e le parti interessate possono accedere alla diretta tramite la sezione Relazioni con gli Investitori del sito web di Inozyme sotto eventi. Una registrazione sarà disponibile per un periodo di tempo dopo la presentazione.
Inozyme Pharma (Nasdaq: INZY), una empresa biofarmacéutica en etapa clínica centrada en desarrollar terapias para enfermedades raras que afectan la salud ósea y la función de los vasos sanguíneos, ha anunciado su participación en la 24ª Conferencia Virtual Anual de Salud de Needham.
El CEO y Presidente de la compañía, Doug Treco, Ph.D., participará en una charla informal programada para el lunes 7 de abril de 2025, de 2:15 a 2:55 p.m. ET. Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Relaciones con Inversores del sitio web de Inozyme en eventos. Una repetición estará disponible durante un tiempo después de la presentación.
이노자임 파마 (Nasdaq: INZY), 뼈 건강과 혈관 기능에 영향을 미치는 희귀 질환을 위한 치료제를 개발하는 임상 단계의 생명공학 회사가 제24회 니드햄 가상 의료 컨퍼런스에 참가한다고 발표했습니다.
회사의 CEO이자 회장인 Doug Treco 박사는 2025년 4월 7일 월요일 오후 2:15부터 2:55까지 ET로 예정된 대화에 참여할 것입니다. 투자자 및 관심 있는 당사자는 이노자임 웹사이트의 투자자 관계 섹션을 통해 생중계에 접근할 수 있습니다. 발표 후 일정 기간 동안 다시보기 서비스가 제공될 것입니다.
Inozyme Pharma (Nasdaq: INZY), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies pour des maladies rares affectant la santé osseuse et la fonction des vaisseaux sanguins, a annoncé sa participation à la 24ème Conférence Virtuelle Annuelle de Needham sur la Santé.
Le PDG et Président de l'entreprise, Doug Treco, Ph.D., participera à une discussion informelle prévue pour le lundi 7 avril 2025, de 14h15 à 14h55 ET. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via la section Relations avec les Investisseurs du site web d'Inozyme sous événements. Un enregistrement sera disponible pendant un certain temps après la présentation.
Inozyme Pharma (Nasdaq: INZY), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapeutika für seltene Erkrankungen konzentriert, die die Knochengesundheit und die Funktion der Blutgefäße betreffen, hat seine Teilnahme an der 24. jährlichen virtuellen Gesundheitskonferenz von Needham bekannt gegeben.
Der CEO und Vorsitzende des Unternehmens, Doug Treco, Ph.D., wird an einem informellen Gespräch teilnehmen, das für Montag, den 7. April 2025, von 14:15 bis 14:55 Uhr ET geplant ist. Investoren und Interessierte können über den Bereich Investor Relations auf der Website von Inozyme unter Veranstaltungen auf die Live-Übertragung zugreifen. Eine Wiederholung wird für eine Zeit nach der Präsentation verfügbar sein.
- None.
- None.
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, from 2:15-2:55pm ET.
A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.
About Inozyme Pharma
Inozyme Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics that target the PPi-Adenosine Pathway, a key regulator of bone health and blood vessel function. Disruptions in this pathway underlie a range of severe diseases, including ENPP1 Deficiency. Our lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to restore PPi and adenosine levels. INZ-701 is currently in late-stage clinical development in ENPP1 Deficiency, with the potential to expand into additional indications where deficiencies in the PPi-Adenosine Pathway contribute to disease pathology. Through our pioneering work, we aim to transform treatment options for patients affected by these devastating conditions.
For more information, please visit www.inozyme.com and follow us on LinkedIn, X, and Facebook.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(617) 461-2442
stefan.riley@inozyme.com
Media:
Biongage Communications
Todd Cooper
(617) 840-1637
todd@biongage.com
FAQ
When is Inozyme Pharma (INZY) presenting at the Needham Healthcare Conference 2025?
How can investors watch Inozyme Pharma's (INZY) Needham Conference presentation?
What type of diseases does Inozyme Pharma (INZY) focus on treating?
What is the format of Inozyme Pharma's (INZY) presentation at the Needham Conference?
